Recent Advances in the Management of Adverse Events Associated with Lorlatinib

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for ALK-positive non-small cell lung cancer (NSCLC).
• It shows significant systemic and intracranial activity in patients progressing on earlier TKIs.
• Lorlatinib presents a distinct safety profile compared to other ALK-TKIs.

Purpose of the Study:

• To review the safety profile of lorlatinib.
• To outline management strategies for lorlatinib-induced adverse events.
• To provide a practical guide for lorlatinib's clinical application.

Main Methods:

• Literature review of lorlatinib's safety and efficacy studies.
• Analysis of reported adverse events and their management.
• Synthesis of clinical data for practical guidance.

Main Results:

• Lorlatinib exhibits notable efficacy in ALK-mutated NSCLC, including brain metastases.
• Key adverse events include hyperlipidemia and central nervous system effects.
• These events are generally manageable with dose modifications or medical therapy, with rare permanent discontinuations.

Conclusions:

• Lorlatinib is an effective treatment option for advanced ALK-positive NSCLC.
• Understanding and managing its unique safety profile is crucial for optimal patient care.
• This review offers practical guidance for clinicians using lorlatinib.